MN HF3026

Amends Minnesota Statutes section 256B.0625, subdivision 64, to expand the exemption of clinical trial treatments from Medical Assistance and EPSDT program coverage to include "any other treatment that is part of an approved clinical trial" as defined in section 62Q.526.

Clarifies that participation in an approved clinical trial does not prevent coverage of medically necessary services unrelated to the trial.

Creates exception allowing EPSDT program coverage of stiripentol if the enrollee is medically determined to need it, has Dravet syndrome or malignant migrating partial epilepsy with specific genetic mutations, has failed other covered medications, and has FDA approval for an individual patient investigational new drug application.

Excludes stiripentol exception from MinnesotaCare coverage under chapter 256L.